VIALE, GIUSEPPE
VIALE, GIUSEPPE
Dipartimento di Oncologia ed Emato-Oncologia
ESR1 testing on FFPE samples from metastatic lesions in HR + /HER2- breast cancer after progression on CDK4/6 inhibitor therapy
2025 K. Venetis, G. Cursano, R. Scafetta, P.P.M.B. Giachetti, A. Concardi, E. De Camilli, M. D'Ercole, E. Mane, C. Frascarelli, A. Marra, S. Gandini, F. Pepe, S. Scagnoli, S.M. Rossi, R. Troiano, E. Speziale, C. De Angelis, G. Troncone, U. Malapelle, G. Perrone, A. Botticelli, G. Viale, G. Curigliano, E. Guerini Rocco, C. Criscitiello, N. Fusco
Inter-Assay Variability of TROP2 Immunohistochemistry in Triple-Negative Breast Cancer
2025 G. Cursano, A. Concardi, M. Ivanova, C. Frascarelli, E. Mane, E. Mangione, S. Santaguida, D. Tosoni, S. Pece, A. Marra, C. Criscitiello, G. Curigliano, G. Viale, K. Venetis, E.G. Rocco, N. Fusco
Breast Immunology Network: Toward a Multidisciplinary and Integrated Model for Breast Cancer Care in Italy
2025 A. Botticelli, O. Brignoli, F. Caruso, G. Curigliano, V. Di Lauro, C. Masini, M. Taffurelli, G. Viale
PIK3CA testing in HR+/HER2- metastatic breast cancer: assessing pathology laboratories capacity and needs
2025 E. Mane, G. Cursano, K. Venetis, C. Frascarelli, F. Pepe, M. Nacchio, L. Palumbo, P. Pisapia, E. De Camilli, I. Castellano, B. Cerbelli, L. Costarelli, G. D'Amati, A. Rizzo, A. Santinelli, C. Scatena, C. Criscitiello, C. De Angelis, M.V. Dieci, G. Troncone, G. Curigliano, G. Viale, E. Guerini-Rocco, U. Malapelle, N. Fusco
Outcomes of patients with advanced solid tumors who discontinued immune-checkpoint inhibitors: a systematic review and meta-analysis
2024 L. Pala, E. Pagan, I. Sala, C. Oriecuia, M. Oliari, T. De Pas, C. Specchia, E. Cocorocchio, E. Zattarin, G. Rossi, C. Catania, G.L. Ceresoli, D. Laszlo, J. Canzian, E. Valenzi, G. Viale, R.D. Gelber, A. Mantovani, V. Bagnardi, F. Conforti
Expression of immune-related genes and breast cancer recurrence in women with ductal carcinoma in situ
2024 E. Guerini-Rocco, F. Bellerba, A. Concardi, S.V. Taormina, G. Cammarata, C. Fumagalli, A. Guerrieri-Gonzaga, D. Macis, E. Del Fiol Manna, E. Balladore, M. Cannone, P. Veronesi, N. Fusco, B. Bonanni, G. Viale, M. Barberis, S. Gandini, M. Lazzeroni
Standardized pathology report for HER2 testing in compliance with 2023 ASCO/CAP updates and 2023 ESMO consensus statements on HER2-low breast cancer
2024 M. Ivanova, F.M. Porta, M. D'Ercole, C. Pescia, E. Sajjadi, G. Cursano, E. De Camilli, O. Pala, G. Mazzarol, K. Venetis, E. Guerini-Rocco, G. Curigliano, G. Viale, N. Fusco
Fine-Tuning Adjuvant Endocrine Therapy for Early-Stage Breast Cancer: An Expert Consensus on Open Issues for Future Research
2024 F. Conforti, L. Pala, T. De Pas, E. Zattarin, C. Catania, E. Cocorocchio, G. Rossi, D. Laszlo, M. Colleoni, A. Zambelli, G.N. Hortobagyi, J. Cortes, M.J. Piccart, M. Dowsett, R.D. Gelber, G. Viale
Tucatinib's journey from clinical development to clinical practice: New horizons for HER2-positive metastatic disease and promising prospects for brain metastatic spread
2023 C. Criscitiello, C. Corti, M. De Laurentiis, G. Bianchini, B. Pistilli, S. Cinieri, L. Castellan, G. Arpino, P. Conte, F. DI MECO, A. Gennari, V. Guarneri, L. Visani, L. Livi, P. Marchetti, F. Puglisi, G. Viale, L. Del Mastro, S. De Placido, G. Curigliano
Immune microenvironment dynamics in breast cancer during pregnancy: impact of gestational age on tumor-infiltrating lymphocytes and prognosis
2023 E. Sajjadi, K. Venetis, M. Ivanova, M. Noale, C. Blundo, E. Di Loreto, G. Scarfone, S. Ferrero, S. Maggi, P. Veronesi, V.E. Galimberti, G. Viale, F.A. Peccatori, N. Fusco, E. Guerini-Rocco
The molecular landscape of breast mucoepidermoid carcinoma
2023 K. Venetis, E. Sajjadi, M. Ivanova, S. Andaloro, S. Pessina, C. Zanetti, A. Ranghiero, G. Citelli, C. Rossi, M. Lucioni, U. Malapelle, F. Pagni, M. Barberis, E. Guerini-Rocco, G. Viale, N. Fusco
Efficacy of Alternative Dose Regimens of Exemestane in Postmenopausal Women With Stage 0 to II Estrogen Receptor-Positive Breast Cancer: A Randomized Clinical Trial
2023 D. Serrano, S. Gandini, P. Thomas, K.D. Crew, N.B. Kumar, L.A. Vornik, J.J. Lee, P. Veronesi, G. Viale, A. Guerrieri-Gonzaga, M. Lazzeroni, H. Johansson, M. D'Amico, F. Guasone, S. Spinaci, B. Bertelsen, G. Mellgren, I. Bedrosian, D. Weber, T. Castile, E. Dimond, B.M. Heckman-Stoddard, E. Szabo, P.H. Brown, A. Decensi, B. Bonanni
ESR1 gene amplification and MAP3K mutations are selected during adjuvant endocrine therapies in relapsing Hormone Receptor-positive, HER2-negative breast cancer (HR+ HER2- BC)
2023 L. Ferrando, A. Vingiani, A. Garuti, C. Vernieri, A. Belfiore, L. Agnelli, G. Dagrada, D. Ivanoiu, G. Bonizzi, E. Munzone, L. Lippolis, M. Dameri, F. Ravera, M. Colleoni, G. Viale, L. Magnani, A. Ballestrero, G. Zoppoli, G. Pruneri
TMEM123 a key player in immune surveillance of colorectal cancer
2023 E. Pesce, C. Cordiglieri, M. Bombaci, S. Eppenberger-Castori, S. Oliveto, C. Manara, M. Crosti, C. Ercan, M. Coto, A. Gobbini, S. Campagnoli, T. Donnarumma, M. Martinelli, V. Bevilacqua, E. De Camilli, P. Gruarin, M.L. Sarnicola, E. Cassinotti, L. Baldari, G. Viale, S. Biffo, S. Abrignani, L.M. Terracciano, R. Grifantini
Advances in Early Breast Cancer Risk Profiling: From Histopathology to Molecular Technologies
2023 C. Pescia, E. Guerini-Rocco, G. Viale, N. Fusco
Outcome of patients with metastatic triple negative breast cancer treated with first-line chemotherapy: a single institution retrospective analysis
2022 N. Bianco, M. Milano, E. Pagan, C. Oriecuia, V. Bagnardi, E.G. Rocco, G.I. Santomauro, G. Peruzzotti, M. Colleoni, G. Viale
LINE1 are spliced in non-canonical transcript variants to regulate T cell quiescence and exhaustion
2022 F. Marasca, S. Sinha, R. Vadala, B. Polimeni, V. Ranzani, E.M. Paraboschi, F.V. Burattin, M. Ghilotti, M. Crosti, M.L. Negri, S. Campagnoli, S. Notarbartolo, A. Sartore-Bianchi, S. Siena, D. Prati, G. Montini, G. Viale, O. Torre, S. Harari, R. Grifantini, G. Solda, S. Biffo, S. Abrignani, B. Bodega
Analytical Performance of Next-Generation Sequencing and RT-PCR on Formalin-Fixed Paraffin-Embedded Tumor Tissues for PIK3CA Testing in HR+/HER2− Breast Cancer
2022 K. Venetis, F. Pepe, E. Munzone, E. Sajjadi, G. Russo, P. Pisapia, M. Ivanova, G. Bonizzi, D. Vacirca, A. Rappa, A. Ranghiero, S.V. Taormina, G. Viale, G. Troncone, M. Barberis, E. Guerini-Rocco, U. Malapelle, N. Fusco
Low-risk triple-negative breast cancers: Clinico-pathological and molecular features
2022 N. Fusco, E. Sajjadi, K. Venetis, M. Ivanova, S. Andaloro, E. Guerini-Rocco, E. Montagna, P. Caldarella, P. Veronesi, M. Colleoni, G. Viale
Role and evaluation of pathologic response in early breast cancer specimens after neoadjuvant therapy: consensus statement
2022 E. Guerini-Rocco, G. Botti, M.P. Foschini, C. Marchio, M.G. Mastropasqua, G. Perrone, E. Roz, A. Santinelli, I. Sassi, V. Galimberti, L. Gianni, G. Viale